| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H19N2O2 |
| Molecular Weight | 223.2915 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
InChI
InChIKey=ALWKGYPQUAPLQC-UHFFFAOYSA-N
InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
| Molecular Formula | C12H19N2O2 |
| Molecular Weight | 223.2915 |
| Charge | 1 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction. Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
CNS Activity
Originator
Approval Year
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Prolonged curarization in a patient with renal failure. Case report. | 1971 May |
|
| Recurarization--fact or fiction. | 1971 Sep-Oct |
|
| Myasthenia syndrome during penicillamine treatment. | 1975 Jun 28 |
|
| On the interaction of drugs with the cholinergic nervous system--V. Characterization of some effects induced by physostigmine in mice: in vivo and in vitro studies. | 1978 Jan 15 |
|
| Neuropharmacology of the parasitic trematode, Schistosoma mansoni. | 1983 Jan |
|
| Effect of halogenated anaesthetics on heart rate changes during reversal of neuromuscular block with glycopyrrolate and neostigmine. | 1984 Nov |
|
| Impairment of the antagonism of vecuronium-induced paralysis and intra-operative disopyramide administration. | 1989 Jan |
|
| Complete heart block following glycopyrronium/neostigmine mixture. | 1989 May |
|
| Sensitivity to both vecuronium and neostigmine in a sero-negative myasthenic patient. | 1989 Oct |
|
| Reversal of antihypertensive agent-induced postural hypotension with physostigmine. | 1991 May-Jun |
|
| Effects of adrenergic blockers on central nervous system-mediated hyperglycemia in fed rats. | 1992 May |
|
| Spinal neostigmine diminishes, but does not abolish, hypotension from spinal bupivacaine in sheep. | 1996 Nov |
|
| A multi-center study of intrathecal neostigmine for analgesia following vaginal hysterectomy. | 1998 Oct |
|
| International Association for the Study of Pain--Ninth World congress. 22-27 August 1999, Vienna, Austria. | 1999 Nov |
|
| The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines. | 2002 Aug |
|
| [Slow channel syndrome due to an autosomal translocation at 2q31-9p27]. | 2002 May |
|
| Ocular myasthenia gravis and auto-immune thyroiditis in children. | 2005 Nov |
|
| Sphincter of Oddi and its dysfunction. | 2008 Jan |
|
| Prucalopride: the evidence for its use in the treatment of chronic constipation. | 2008 Jun |
|
| Interventions for heartburn in pregnancy. | 2008 Oct 8 |
|
| Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis. | 2009 May |
|
| Dr Lazar Remen (1907-74): a forgotten pioneer in the treatment of myasthenia gravis. | 2009 May |
Patents
Sample Use Guides
The recommended dose range of Neostigmine Methylsulfate Injection is 0.03 mg/kg to 0.07 mg/kg administered as an intravenous bolus.
Route of Administration:
Intravenous
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3982TWQ96G | PRIMARY | |||
|
D009388 | PRIMARY | |||
|
DTXSID1023360 | PRIMARY | |||
|
4456 | PRIMARY | |||
|
7315 | PRIMARY | RxNorm | ||
|
SUB03411MIG | PRIMARY | |||
|
NEOSTIGMINE | PRIMARY | |||
|
DB01400 | PRIMARY | |||
|
1897 | PRIMARY | |||
|
m7819 | PRIMARY | Merck Index | ||
|
3982TWQ96G | PRIMARY | |||
|
CHEMBL278020 | PRIMARY | |||
|
C75024 | PRIMARY | |||
|
3921 | PRIMARY | |||
|
59-99-4 | PRIMARY | |||
|
Neostigmine | PRIMARY | |||
|
100000085714 | PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|